Crispr Therapeutics AG (NASDAQ:CRSP) saw a significant decline in short interest during the month of June. As of June 15th, there was short interest totalling 5,122,100 shares, a decline of 6.2% from the May 15th total of 5,459,700 shares. Based on an average trading volume of 549,800 shares, the days-to-cover ratio is currently 9.3 days. Approximately 19.4% of the company’s shares are short sold.
CRSP has been the subject of a number of recent analyst reports. BTIG Research upped their price objective on Crispr Therapeutics from $30.00 to $33.00 and gave the company a “buy” rating in a report on Monday, April 22nd. BidaskClub downgraded YRC Worldwide from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th. Evercore ISI began coverage on Homology Medicines in a research note on Thursday, April 11th. They issued an “outperform” rating and a $29.00 target price for the company. Roth Capital began coverage on Crispr Therapeutics in a research note on Monday, June 10th. They issued a “buy” rating and a $50.00 target price for the company. Finally, Needham & Company LLC reissued a “buy” rating and issued a $10.00 target price (down from $15.00) on shares of Nabriva Therapeutics in a research note on Wednesday, May 1st. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $49.88.
Shares of CRSP stock traded down $0.07 on Friday, hitting $49.11. 287,431 shares of the stock were exchanged, compared to its average volume of 566,607. The company has a debt-to-equity ratio of 0.08, a current ratio of 15.84 and a quick ratio of 15.84. The stock has a market cap of $2.60 billion, a price-to-earnings ratio of -14.28 and a beta of 3.11. The business has a 50-day moving average of $43.23. Crispr Therapeutics has a fifty-two week low of $22.22 and a fifty-two week high of $66.26.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, April 29th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.03). The firm had revenue of $0.30 million for the quarter, compared to analyst estimates of $1.50 million. Crispr Therapeutics had a negative return on equity of 50.90% and a negative net margin of 8,839.02%. The firm’s quarterly revenue was down 78.6% on a year-over-year basis. During the same period in the prior year, the company earned ($0.62) earnings per share. As a group, equities research analysts expect that Crispr Therapeutics will post -3.82 earnings per share for the current fiscal year.
In related news, President Rodger Novak sold 50,000 shares of the company’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $50.00, for a total value of $2,500,000.00. Following the completion of the sale, the president now owns 848,007 shares in the company, valued at $42,400,350. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Samarth Kulkarni sold 20,000 shares of the company’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $46.00, for a total value of $920,000.00. Following the completion of the sale, the chief executive officer now owns 185,801 shares of the company’s stock, valued at approximately $8,546,846. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 160,000 shares of company stock valued at $7,511,000. 21.40% of the stock is currently owned by corporate insiders.
Hedge funds have recently bought and sold shares of the company. Valeo Financial Advisors LLC boosted its position in shares of Crispr Therapeutics by 71.4% during the first quarter. Valeo Financial Advisors LLC now owns 725 shares of the company’s stock worth $26,000 after buying an additional 302 shares during the period. Resources Investment Advisors Inc. acquired a new position in Crispr Therapeutics during the fourth quarter valued at approximately $43,000. Lenox Wealth Management Inc. boosted its position in Crispr Therapeutics by 1,731.7% during the first quarter. Lenox Wealth Management Inc. now owns 2,198 shares of the company’s stock valued at $79,000 after purchasing an additional 2,078 shares during the last quarter. Dubuque Bank & Trust Co. boosted its position in Crispr Therapeutics by 101.6% during the first quarter. Dubuque Bank & Trust Co. now owns 2,873 shares of the company’s stock valued at $103,000 after purchasing an additional 1,448 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in Crispr Therapeutics by 79.4% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,987 shares of the company’s stock valued at $112,000 after purchasing an additional 1,765 shares during the last quarter. 48.96% of the stock is owned by institutional investors.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.